BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) announced the publication of a study conducted by Cyclacel scientists showing synergistic activity between its investigational therapy seliciclib and multiple epidermal growth factor receptor (EGFR) inhibitors, including erlotinib (Tarceva®) in models of non-small cell lung cancer and the HER2 targeting agent, trastuzumab (Herceptin®) in models of breast cancer. These preclinical results were published in the July issue of the journal, Clinical Cancer Research*. Seliciclib, Cyclacel’s orally available cyclin dependent kinase (CDK) inhibitor, is currently being tested as a single agent in the Phase 2b APPRAISE trial in patients with non-small cell lung cancer and in a Phase 2 study in patients with nasopharyngeal cancer.
